Citation: Wang S., Zhang S. Leveraging budding yeast Saccharomyces cerevisiae for discovering aging modulation substances for functional food. Functional Foods in Health and Disease 2019; 9(5): 297-311. https://doi.org/10.31989/ffhd.v9i5.575 ABSTRACT Functional food has been a practical mean to be used for health promotion and morbidity compression in the aging population. The discovery and development of bioactive substances with aging modulation actions are critical steps for more potent and safer functional food for aging modulation. Budding yeast (Saccharomyces cerevisiae), as a single-cell eukaryotic organism, displays genes, molecular and cellular mechanisms conserved with mammalians. It is a well-developed model for replicative and chronological aging in mammalians. This model organism, with its amenability by genetic and molecular tools, have thus served well for discovering bioactive compounds for aging modulation and health promotion of a variety of age-related health conditions in humans.
characteristics of the yeast makes this organism as an important aging model for more complex organisms including humans. (Table 1) . Replicative aging and chronological aging phenotypes in budding yeast have been used to model aging of stem cells and post-mitotic cells, respectively, in the higher organisms including humans.
Figure 1
Aging is characterized as a functional decline of living units (cells, tissues, whole organisms) from yeast to humans.
http://njms.rutgers.edu/departments/cell_biology_and_molecular_medicine/documents/Yeast_Ag ing_02_09_2015_Ivessa_MolecularMechanismsodDiseases.pdf )
The budding yeast displays the most hallmarks of aging in higher eukaryotes including humans [13] . For example, genomic instability [14] , epigenetics [15] and proteostasis [16] have been empirically demonstrated in yeast. Additionally, its amenability by genetic, molecular biology and high-throughput tools makes this organism an invaluable tool for discovering bioactive substances that modulate aging processes (Table 1 ). This single cell organism has also contributed to the understanding of a very crucial question in aging research landscape: most eukaryotic organisms are aging, but why age-induced changes are not transmitted to the progeny? A seminal study on yeast has shown that resetting of lifespan occurs during gametogenesis, and transient induction of a transcription factor essential for later stages of gametogenesis extends the replicative lifespan of aged cells [17] .
Considerable understanding of aging process and rejuvenation in yeast, conservation to humans and amenability with a range of biotechnological tools thus warrant this organism as a system for discovering bioactive substance for intervening aging including preventing, slowing and even reversing or rejuvenating aging, in addition to genetic approaches and dietary restriction [27, 28] . We conceptualised four approaches using the yeast systems for achieving this purpose: discovering targets for aging modulation; uncovering and validating dietary restriction (DR) mimetics; acting as cellular systems for screening natural products or synthetic compounds for aging modulation and being a biological factory for producing bioactive compounds. [21] [22] [23] [24] [25] , also enabling to variation of aging phenotypes at an individual cells level [26] . This is in sharp contrast to in vitro non-cell based approaches * Note: powerful genetics, proteomics, completely sequenced genome, comprehensive single gene deletion and overexpression libraries, determination of protein localization in vivo and tandem affinity purification-tagging approaches and synthetics biology; Saccharomyces Genome Database (SGD) -https://www.yeastgenome.org/ and other bioinformatics tools.
DISCOVERING TARGETS FOR AGING MODULATION:
Budding yeast provides powerful single cell systems to discover or validate genes, molecular and cellular pathways of aging. This organism displays the most of known hallmarks of aging relevant in higher eukaryotes including humans [13] . For example, genomic instability [14] , epigenetics [15] and proteostasis [29] have been empirically demonstrated in yeast. An important pathway that is closely relevant to functional food is the nutrient sensing and regulation pathway -Insulin/IGF-I and related signalling pathways (Figure 2 ). Cell membrane receptors and intracellular cascade of signalling pathways and till the gene expressions via transcriptional factors are shown to be remarkably conserved among these organisms. These genes, proteins and components of the pathways of the aging hallmarks can be the targets for discovering and developing compounds for modulating aging including preventing, delaying and reversing aging, and treating aging-related diseases [14, 15, 30, 31] .
Figure 2:
The conservation of nutrients sensing and regulation pathways from yeast to rodents [32] .
The recent discovery of yeast protein kinase Sch9 that adjusts V-ATPase assembly/disassembly to control pH homeostasis and longevity in response to glucose availability may be proven to be a useful target in discovering bioactive for aging modulation [33] . A 2017 study has pushed the frontier further. Pol III was discovered as a pivotal output of the target of rapamycin (TOR) nutrient signalling network for longevity, and the evolutionary conservation of Pol III warrants its potential as a therapeutic target [34] . Sir2 family of genes and proteins have been the well-known targets for developing aging modulating compounds which were discovered initially in the budding yeast [35] . The yeast silent information regulator 2 (SIR2) gene, which conferred sirtuins their family name, was first shown to extend lifespan in yeast two decades ago. The sirtuin proteins are NAD + dependent protein deacetylases that serve as regulatory functions through deacetylation of histone and a wide range of other proteins. As Bonkowski and Sinclair [31] noted, more than 14,000 sirtuin-activating compounds (STACs) have been synthesized thus far, and a handful have been subjected to be tested in animal models of type 2 diabetes, colitis, neurodegeneration, fatty liver and atherosclerosis, among others [36] . STACs now are in their fifth generation and some have more than 1,000-fold greater potency in vitro than resveratrol. The STAC named SRT2104, which mimics aspects of calorie restriction and extends male mouse lifespan, has advanced through multiple phase I trials with few, if any, side effects to phase II trials. Two SRT2104 clinical trials in elderly volunteers and otherwise healthy smokers showed a slight reduction in body weight, a 15-30% improvement in the cholesterol ratio and a 19% decrease in triglyceride levels [36] ( Table 2 ). The resveratrol is, however, still the best known sirtuins activator and importantly it is present in various diet sources such as grape skin, apple and peanuts [37, 38] and it is well into the clinical trials [37] . It is very exciting to see the target driven approach in working to discover the bioactive compounds for functional food. However, it must be kept in mind that it is necessary that animal tests, clinical trials, and epidemiology studies need to be carried out for their other properties needed for the treatment of age-related diseases. A 9 years follow-up study (outcomes at 3 rd , 6 th and 9 th year) of resveratrol as part of the diet of 769 participants aged 65 years and older, showed the inverse relationship between concentrations of diet and urinary resveratrol and frailty syndrome, supporting that the resveratrol can be effective in preventing certain age-related diseases in humans. However, limited high-quality clinical trials of resveratrol showed that more trials are still needed, particularly in regard to its bioavailability and in varied populations [42] .
The budding yeast is also an excellent model for understanding aging-related diseases such as neurological diseases in humans [19] . Human genes for particular age-related diseases have been successfully incorporated into yeast genome and have been expressed [43, 44] . The human genes and their products can then be used as targets in yeast systems for discovering bioactive compounds including those in functional food. For example, human β-secretase that plays an important role in Alzheimer's disease (AD) pathology has been expressed in yeast and its inhibitors have been subsequently identified [45, 46] . Middendorp et al. [46] have used the yeast system that expressed human β-secretase to validate the BACE-1 inhibitors as target specific compounds. This approach is applicable in high-throughput screens for selecting inhibitors of defined secretases acting on natural substrates in a membrane-bound protein configuration. Promising phytochemicals indicated from various means [47] can be subjected to high-throughput screening for their potential for AD prevention or therapeutic agents [22] .
Another relevant example of yeast aging pathways as targets for humans aging is the autophagy, which is a recycling pathway within cells that delays aging via eliminating injured organelles and other molecules [48] [49] [50] . The pathway and longevity in yeast have been shown to be positively modulated by a bioactive, the ethanolamine which is a precursor of phosphatidylethanolamine [50] . This chemical is widely used in cosmetics, lifestyle, and household products such as hair colours, washing powders, and so forth [50, 51] which is reported to be tolerated by human skin. Whether this chemical can be fortified in functional food, and the efficacy and safety of ethanolamine-containing food remains as an interest to pursue. It is noted here, that compounds that targeting autophagy for aging modulation are largely unexplored [52] . Possible targets for aging modulation may also come from the metabolomics studies. Various methods for metabolite profiling at single-cell, few-cells and population levels and during aging process of yeast have been developed [53, 54] .
The accumulating evidence suggests that yeast continues to be an excellent system for discovering targets for aging modulation, treatment of diseases of aging, and beyond for other human diseases such as diabetes mellitus due to its capacity to be humanized by various approaches.
DISCOVERING AND VALIDATING DIET RESTRICTION MIMETICS:
Dietary restriction (DR) defined as the food restriction without malnutrition is a major, scientifically proven mean for aging modulation and health promotion from yeast to nonhuman mammals [55] [56] [57] , and evidence is emerging for humans too [58] . However, its application to humans is proven to be difficult, due to psychology and lifestyle issues. In response to these issues, DR mimetics known as drugs that mimic beneficial effects of dietary restriction without malnutrition, are being developed [59] . DR in present paper refers specifically to caloric restriction and amino acids restriction. Considerable understanding of pathways underlying DR in regulating yeast longevity and aging has been made, including Snf1 (AMPK-AMP-activated protein kinase) signalling pathway [60] , TOR (target of rapamycin) pathway [61] , Sir2 pathway [62] and cell cycle program [63] . While SIR2 pathway is responsive to caloric restriction, the TOR pathway is for amino acids sensing [61] .
The identification and validation of DR mimetics using yeast as a model have been explored, particularly due to the close link of DR to nutrient sensing pathways [64, 65] . The resveratrol, a plant polyphenol was first identified as DR-mimetics in yeast, acting on sirtuins pathway by 'monitoring' low-energy states via detecting high NAD + levels. Resveratrol elicits physiological changes mimicking DR, leading to improved tissue pathology, increased endurance, mitochondrial biogenesis, energy expenditure, insulin sensitivity, and decreased fat accumulation, blood insulin and IGF-1 in higher eukaryotes [66, 67] . Compounds that raise NAD + levels, such as nicotinamide riboside and nicotinamide mononucleotide (NMN) as described above show a great promise as DR-mimetics to treat numerous age-related conditions in humans.
Activators, both synthetics and natural compounds, of AMPK pathway have also been identified. More than 100 natural products or extracts derived from plants including those for Asian medicines have been demonstrated to activate AMPK [68] . For example, berberine [69, 70] , and arctigenin [71] seem to activate AMPK by inhibiting the mitochondrial respiratory chain and galegine, a natural product from the medicinal plant Galega officinalis from which metformin and phenformin were derived [72] . More details on these natural compounds can be found in the paper by Hardie [68] . As the mechanisms of actions of most of these compounds have not been explored, yeast, with its advantageous features for aging modulation, can be leveraged for elucidating such mechanisms and qualifying their capacity as DR-mimetics as parts of functional food. Relevance of AMPK pathway and subsequent mimetics to human diseases of aging renders studies on this pathway as an emerging research area [73] . However, it is useful to be reminded that AMPK pathway can control intrinsic aging in yeast independent of DR [74] . Other known or potential DR-mimetics including polyphenols (such as quercetin, anthocyanin, and curcumin), lactoferrin, lutein, and eicosapentaenoic acid may be investigated at molecular levels using yeast system for their efficacy and mechanisms of action in aging modulation in yeast [75] .
ACTING AS CELLULAR SYSTEMS FOR SCREENING NATURAL PRODUCTS OR SYNTHETIC COMPOUNDS FOR AGING MODULATION:
Single cell eukaryote budding yeast displays three aging phonotypes: replicative, chronological and colony aging which represents the three states of cells in multicellular organisms including humans, i.e. models for aging of mitotic cells including stem cells (dividing), post-mitotic tissues (non-dividing, i.e. functioning cells) and potentially multicellular tissue in mammals ( Table 1 ). The strongest advantage of this organism is that it is easily amendable to various methods of high throughput screening assays. This is nearly unmatched by any other model organisms for an aging study [21, 22, 24, 27] .
The replicative aging phenotypes have been assessed by various screening tools. The limiting factor in studying this phenotype is the difficulty in separating daughter cells from mother cells. The pioneering work by Mortimer and Johnston in 1959, used micromanipulation physically to remove daughter cells from mothers under the microscope [76] . However, this assay is not easy to perform and is labour intensive although it remains as the standard method. Particularly, it is not amendable to large scale screening assay. Various means are then developed to separate the mothers from daughters for high-throughput assays. Using genetic methods, the mothers can be enriched, where the daughter cells are genetically eliminated. This genetic methods provide a simplified screening method for identifying genetic or environmental factors that regulate replicative aging [77] . Taking the advantage of size difference between mother and buds, physical separation of mothers and daughter have been made using microfluidics and mechanical principals [24, 78] . Separation of mother cells from daughter cells have been made by leveraging the knowledge of the previously synthesized components of the mother cell surface do not contribute to the daughter cell surface. A biotinavidin system has been used to harness knowledge in which mother cells are labelled with biotin and then grown for desired number of generations. The labelled mothers in the culture are then extracted using a streptavidin-coated magnetic beads [79] .
The chronological aging has also been subjected to a high throughput screen with the outgrowth assay as the readout. A high-throughput method for measuring chronological aging involves first growing yeast cultures to stationary phase in individual wells of a 96-well plate. At various intervals (time points), a sample (e.g. 1 μL) from each well is transferred into a corresponding well of a second 96-well plate containing the usual amount (e.g. 200 μL) of fresh media. This second plate is incubated for a short period (e.g. 24 h) at a constant temperature, after which the optical density (OD) at 600 nm of each well is determined using a plate-reader. This OD corresponds to the number of viable cells in the inoculum [80, 81] .
Yeast cells obtained in these two types of high-throughput assays of aging have been exploited for discovering anti-aging compounds. Lithocholic acid as an anti-aging compound has been identified as being able to extend yeast chronological life span in a TOR-independent manner [81] . Another example is that, in 2014, glyceollin I, an induced phytoalexin in soybeans were discovered. It extends yeast life span at low (nM) doses in a calorie restriction (CR)-dependent manner. The glyceollin I might be a promising DR-mimetic candidate, and the high contents of glyceollins in soybeans could improve its bioactivity as functional food ingredients [82] . The same year, yeast was also used for screening more than 100 botanical materials. This screen identified tanshinones that extend chronological lifespan up to 2.5 times compared with control [83] .
It is anticipated that continued screening of natural products using various aging assays, coupled with ever developed new tools for modulating aging processes [27] will be conducted, especially in the context of seemingly abundant amount of natural materials and the quest for more potent, safer medicine and functional food for better health via aging modulation.
BEING A BIOLOGICAL FACTORY FOR PRODUCING BIOACTIVE COMPOUNDS:
Yeast can also serve as a biological factory for producing bioactive compounds for modulating aging [84, 85] . The rationale for this approach is that direct extraction of bioactive compounds from natural biological sources can be inefficient, due to the low concentrations of these compounds, and their chemical synthesis is often difficult to achieve because of their complex structures. In recent years, the discovery of genes involved in the synthetic pathways of the metabolites, combined with synthetic biology tools, has allowed the construction of yeast cell factories for the production of these metabolites from renewable biomass [86] .
There are several characteristics making yeast as cell factories for bioactive compounds production. First, complete synthetic pathways can be assembled in a single step including subcellular pathways engineering [87] [88] [89] [90] [91] . For example, a gene cluster that contains four plantderived genes of the early flavonoid biosynthetic pathway is constructed to allow the conversion of phenylpropanoid acids into flavanones in budding yeast [89] . Second, the yeast is amendable using the latest gene editing tool the CRISPRCas9 technology. For example, the mevalonate pathway created using this technology in yeast, has produced the mevalonate titers greater than 41-fold compared to the wild-type strain [92] . This technology has not been used widely in aging modulation research yet at least in term of production of important natural bioactive compounds in large quantity and more economical manner. Other examples are the flavonoids, stilbenoids (e.g. quercetin, kaempferol and resveratrol), ginsenoside and melatonin produced using this approach [84, [93] [94] [95] . However, the public perception and acceptance of the genetically modified health promotion medicine or substance can be an issue. This approach nevertheless is an excellent tool for producing bioactive aging modulation compounds is clearly largely underexplored.
Figure 3
Four approaches using Yeast (Saccharomyces cerevisiae) system for functional food have been developed.
CONCLUSIONS
In this paper, we argue that four approaches exist to produce effective medicinal products for aging modulations that are applicable to humans. The powerful approach of yeast being the cell factories for aging modulation research has unfortunately been largely unexplored, but the opportunity is clear. With these approaches in mind, it is conceivable that efficiently quantifying aging modulating effects of functional food for health is becoming practical. The knowledge gained in using these approaches will greatly facilitate pre-clinical development of ever better medicine for prevention, slowing and treating of aging and diseases of aging in this ever-aging population.
Abbreviations: DR: Diet restriction encompasses both of caloric restriction (CR) and diet restriction (DR) of nutrients such as amino acids. Other common abbreviations include Alzheimer's disease (AD); sirtuin-activating compounds (STACs); target of rapamycin (TOR); nicotinamide mononucleotide (NMN).
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